Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors

Background Sunitinib is an oral multitargeted tyrosine kinase inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptors, as well as of other receptor types. We have performed a feasibility study to investigate the safety of sunitinib in combination with pemetrexed...

Descripción completa

Detalles Bibliográficos
Autores principales: Okamoto, Isamu, Shimizu, Toshio, Miyazaki, Masaki, Tsurutani, Junji, Ichikawa, Yasuko, Terashima, Masaki, Takeda, Masayuki, Fumita, Soichi, Ohki, Emiko, Kimura, Nobuyuki, Hashimoto, Junichi, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2010
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3277823/
https://www.ncbi.nlm.nih.gov/pubmed/20960028
http://dx.doi.org/10.1007/s10637-010-9565-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3277823/
https://www.ncbi.nlm.nih.gov/pubmed/20960028
http://dx.doi.org/10.1007/s10637-010-9565-5

Ejemplares similares